IOM On “Omics” Assays: Stricter Controls Are Needed For Development Process
This article was originally published in The Gray Sheet
Executive Summary
The Institute of Medicine recommends a highly controlled, step-wise approach to bringing complex genomic, proteomic and similar assays from basic research to clinical testing. FDA needs to play a central role, IOM stresses in a recent report.
You may also be interested in...
FDA Agrees To Waive User Fees For Reviews Of Lab-Developed Tests
Although FDA is still developing its lab-developed test regulatory framework, it has agreed not to collect user fees to support its planned review of the tests.
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: